Table 3.
Group | 2-OA–BSA | α-GalCer | IgM anti-PDC-E2† | IgG anti-PDC-E2† |
---|---|---|---|---|
CD4+/+ | – | – | 0·098 ± 0·112 | 0·058 ± 0·009 |
CD4+/+ | + | – | 0·606 ± 0·069 | 0·813 ± 0·122 |
CD4+/+ | + | + | 0·878 ± 0·123** | 1·131 ± 0·096** |
CD4−/− | – | – | 0·105 ± 0·013 | 0·084 ± 0·037 |
CD4−/− | + | – | 0·236 ± 0·039*** | 0·138 ± 0·002*** |
CD4−/− | + | + | 0·764 ± 0·169** | 0·102 ± 0·017*** |
**P < 0·05 and **P < 0·01 compared to CD8−/− 2-octynoic acid conjugated bovine serum albumin (2-OA–BSA/PBS) controls. ***P < 0·05 compared to CD4+/+ 2-OA–BSA-primary biliary cirrhosis (PBC) controls.
Optical density ± standard error of the mean. α-GalCer = α-galactosylceramide; PDC-E2 = E2 subunits of the pyruvate dehydrogenase complex; Ig = immunoglobulin.